a Committee of Hypertension and Kidney disease, Kanagawa Physicians Association , Yokohama , Japan.
b Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine , lsehara , Japan.
Clin Exp Hypertens. 2019;41(7):637-644. doi: 10.1080/10641963.2018.1529778. Epub 2018 Oct 29.
Decrease in blood pressure contributes to the reno-protective effects of sodium-glucose cotransporter 2 inhibitors; however, its relationship with home monitoring of blood pressure is unclear. We retrospectively analyzed 101 visiting members of the Kanagawa Physicians Association with type 2 diabetes mellitus and chronic kidney disease who were taking sodium-glucose cotransporter 2 inhibitors and who monitored blood pressure at home for a median treatment period of months. . The mean blood pressure both at office and home significantly decreased, and there was a significant positive correlation between the change in albumin-creatinine ratio and both blood pressures. Controlled hypertension, masked hypertension, white coat hypertension, and sustained hypertension were observed in 10.9%, 13.9%, 12.9%, and 62.4% of patients at the initiation of therapy, which changed to 10.9%, 16.8%, 17.8%, and 54.5% at the time of the survey, respectively. In conclusion, management of blood pressure both at office and home was found to be important for the reno-protective effects of sodium-glucose cotransporter 2 inhibitors along with strict blood pressure management.
血压降低有助于钠-葡萄糖共转运蛋白 2 抑制剂的肾保护作用;然而,其与家庭血压监测的关系尚不清楚。我们回顾性分析了 101 名参加神奈川医师协会的 2 型糖尿病和慢性肾脏病患者,这些患者正在服用钠-葡萄糖共转运蛋白 2 抑制剂,并在家中监测血压,中位治疗时间为个月。办公室和家庭的平均血压均显著降低,白蛋白-肌酐比值的变化与两种血压均呈显著正相关。在治疗开始时,分别有 10.9%、13.9%、12.9%和 62.4%的患者出现控制性高血压、隐匿性高血压、白大衣性高血压和持续性高血压,而在调查时,分别有 10.9%、16.8%、17.8%和 54.5%的患者出现上述情况。总之,办公室和家庭血压管理对于钠-葡萄糖共转运蛋白 2 抑制剂的肾保护作用很重要,同时需要严格的血压管理。